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Abstract
Objectives. To determine Bruton’s tyrosine kinase (BTK) protein and phosphorylation levels in B cell subsets of
granulomatosis with polyangiitis (GPA) patients and to investigate the effect of BTK blockade on in vitro B cell cytokine
production, subset distribution and (auto)antibody production.
Methods. BTK protein and phosphorylation levels were determined by flow cytometry in peripheral blood B cells of 29
untreated GPA patients [9 active and 20 remission GPA patients (10 ANCA and 10 ANCA+)], 9 age- and sex-matched
healthy controls (HCs) and 9 untreated active RA patients. The effect of BTK blockade on in vitro B cell cytokine pro-
duction, subset distribution and (auto)antibody production was determined in the same donors in peripheral blood
mononuclear cell cultures.
Results. BTK protein levels were significantly increased in transitional and naı¨ve B cells of active GPA and RA patients
compared with remission GPA patients and HCs. Both B cell subsets of active patients were more sensitive to B cell
receptor stimulation, as BTK and phospholipase Cg2 phosphorylation were increased in these patients. In vitro BTK
blockade had profound effects on B cell cytokine production, plasma cell formation and (auto)antibody production in
both GPA patients and HCs. Interestingly, the effect of BTK blockade was less pronounced in active GPA patients,
possibly due to increased activation of B cells.
Conclusion. We show that BTK protein and phosphorylation levels are most profoundly increased in newly emerging B
cells of active GPA patients compared with remission patients. BTK blockade greatly inhibits in vitro B cell effector
functions in GPA patients and HCs. These promising data identify BTK as an interesting novel therapeutic target in the
treatment of GPA.
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Rheumatology key messages
. Bruton’s tyrosine kinase levels are increased in transitional and naı¨ve B cells of active granulomatosis with
polyangiitis patients.
. Bruton’s tyrosine kinase blockade inhibits in vitro B cell effector functions in granulomatosis with polyangiitis
patients and healthy controls.
. Bruton’s tyrosine kinase might be an interesting novel therapeutic target in the treatment of granulomatosis with
polyangiitis.
Introduction
Granulomatosis with polyangiitis (GPA) is an autoimmune
disease that affects small- to medium-sized blood vessels
[1] and is characterized by the presence of ANCA,
predominantly directed against PR3. Although progress
has been made in the understanding of the disease
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mechanisms, GPA and its treatment are still associated
with high disease burden and mortality [1, 2]. Even with
appropriate treatment, 50% of patients experience a
disease relapse in <4 years, often resulting in irreversible
loss of organ function and necessitating toxic immuno-
suppressive therapy [3]. As precursors of autoantibody-
producing cells, B cells are crucially involved in the GPA
pathogenesis. In addition, B cells can also present antigen
[4] and produce pro- and anti-inflammatory cytokines that
have been linked to GPA pathogenesis [5, 6, 7]. GPA
patients display shifts in circulating B cell subsets during
active disease and remission [8]. This is characterized
by increased naı¨ve and decreased memory B cell
frequencies compared with healthy controls (HCs) [8].
Additionally, increased circulating plasmablast frequen-
cies during remission were associated with decreased re-
lapse-free survival [9]. Together, this evidence suggests
that B cells function not only as precursors of autoanti-
body-producing cells, but also as important effector cells
in GPA pathogenesis. Therefore, modulation of abnormal
B cell function might be beneficial in GPA.
It has been demonstrated that aberrancies in Bruton’s
tyrosine kinase (BTK) levels may contribute to abnormal-
ities in B cell activity or subset distribution. BTK is a critical
mediator of B cell receptor (BCR) signalling and has an
important role in B cell growth and differentiation [10].
Upon antigen binding to the BCR, phosphorylated BTK
(pBTK) initiates a downstream signalling cascade that
eventually leads to activation of extracellular signalre-
lated kinase (ERK), protein kinase B (also known as
AKT) and the transcription factor nuclear factor-kB, pro-
moting B cell survival, proliferation and differentiation [10].
Mounting evidence indicates that BTK is an important
factor in autoimmune disease pathogenesis, as BTK over-
expression in murine B cells is sufficient to induce a spon-
taneous autoimmune phenotype [11], and BTK inhibition is
an effective treatment in many murine autoimmune
models [12]. Aberrant BTK activity was also demonstrated
in human autoimmune diseases such as primary SS and
RA [13, 14]. In untreated SS patients, BTK levels were
increased in peripheral B cell subsets, including naı¨ve B
cells, compared with HCs [14]. These levels correlated
with BTK phosphorylation, serum autoantibodies, circulat-
ing T follicular helper (Tfh) cells and infiltrating T cell num-
bers in salivary glands. Similarly, in ACPA+ RA patients,
BTK protein levels were increased compared with ACPA
RA patients and HCs, and correlated with inducible T cell
costimulator (ICOS) expression on Tfh cells [14]. As B
cells and ANCA play an important role in the GPA patho-
genesis, it is possible that BTK activity is also dysregu-
lated in GPA patients.
In this study, we aimed to investigate BTK protein levels
and phosphorylation in B cell subsets of active and remis-
sion GPA patients. Additionally, phosphorylation levels of
other proteins up- and downstream of BTK were studied.
Also, the effect of BTK blockade on in vitro B cell cytokine
production, plasma cell formation and (auto)antibody pro-
duction was investigated.
Methods
Study population
We included nine active and 20 remission GPA patients
(10 ANCA GPA patients; Table 1). Also, nine age-
matched HCs (44.4% male, median age 56.8 years;
range 2274 years) and nine untreated ACPA+ RA
patients, fulfilling ACR/EULAR 2010 classification criteria
for RA [15], from the Rotterdam Early Arthritis Cohort [16]
were included as active disease controls. GPA was diag-
nosed according to Chapel Hill Consensus Conference
definitions and ACR classification criteria [17, 18]. Active
and remission GPA was diagnosed by clinical and labora-
tory evaluation. Active GPA had to result in start/increase
of immunosuppressive medication. Remission was
defined as absence of any clinical/laboratory signs of
active disease and a BVAS of zero. None of the patients
received immunosuppressive treatment. ANCA titres of
41:20 were considered negative. Two patients received
rituximab for >3 years before sampling. This study was
approved by the medical ethics committee of the
University Medical Center Groningen (METc no. 2012/
151), informed consent was obtained from all patients
and the study complies with the Declaration of Helsinki.
Peripheral blood mononuclear cell culture assays
Peripheral blood mononuclear cells (PBMCs) were iso-
lated, frozen and thawed as described previously [19].
For all cultures, 1 106 PBMCs/ml were cultured with or
without 1000 nM BTK blocker (BMS-986142, kindly pro-
vided by BristolMyers Squibb, New York, NY, USA [20]).
The BTK blocker was pre-incubated for 1 h.
TABLE 1 Patient characteristics
Active GPA patients
Remission GPA
patients
Active ACPA+ RA
patients HCs
Subjects, n (% male) 9 (55.6) 20 (40) 9 (11.1) 9 (44.4)
Age years, mean (range) 57.2 (21.578.3) 59.5 (2677.8) 56.3 (35.175.8) 56.8 (2274)
Autoantibody titre, median (range) 1:160 (1:401:640) 1:80 (01:640) (U/ml) 96 (141802) 
Creat mmol/ml, median (range) 82 (62151) 93.5 (57409) NA 
CRP mg/ml, median (range) 43.5 (9268) 3.4 (0.538) 5 (117) 
BVAS, median (range) 15 (821) 0 DAS28: 4.3 (2.06.8) 
Creat: creatinine; GPA: granulomatosis with polyangiitis; HC: healthy control; NA: not applicable.
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To investigate the effect of BTK inhibition on B
cell cytokine production, PBMCs were cultured for
3 days with 1000 nM anti-IgM Fab2 fragments (Jackson
ImmunoResearch, West Grove, PA, USA) and restimu-
lated for the last 4.5 h with 50 ng/ml phorbol myristate
acetate and 2 mM calcium-ionophore in the presence of
10 mg/ml brefeldin A (SigmaAldrich, St. Louis, MO, USA).
To assess the effect of BTK inhibition on plasma cell
formation, PBMCs were cultured for 7 days with 1000 nM
anti-IgM Fab2 fragments (Jackson ImmunoResearch) and
100 ng/ml B cell activating factor (BAFF; PeproTech Inc.,
Rocky Hill, NJ, USA).
To determine the effect of the BTK blocker on
(auto)antibody production, PBMCs were cultured for
12 days with 1000 nM anti-IgM Fab2 fragments (Jackson
ImmunoResearch), 100 ng/ml BAFF and 100 ng/ml IL-21
(ImmunoTools, Friesoythe, Germany) [21].
BTK protein levels and T cell subsets by flow
cytometry
BTK protein levels in B and T cell subset frequencies
were assessed ex vivo by flow cytometry as described
previously [13]. For antibodies used, see supplementary
Table S1, available at Rheumatology online. For gating
strategy, see supplementary Figs S1 and S2, available
at Rheumatology online. The BTK protein staining was
validated using isotype controls and FMOs (fluorescence
minus one). The levels of background staining in B and T
cells were similar. To account for background in the BTK
staining, ratios were calculated by dividing the mean fluor-
escence intensity (MFI) of BTK protein in B cell subsets by
the MFI in T cells within each sample, as T cells do not
express BTK (supplementary Fig. S1, available at
Rheumatology online). Data were analysed using FlowJo
software (Treestar, Ashland, OR, USA).
Phosphorylation of signalling molecules by
phosphoflow
To determine ex vivo phosphorylation of intracellular sig-
nalling molecules, 4105 PBMCs/sample were kept at
4C and directly fixed with FoxP3-staining kit Fix/Perm
solution (eBioscience, San Diego, CA, USA). Samples
were stained for 30 min at 4C with a staining cocktail to
identify B cell subsets, followed by the antibody targeting
the phosphorylated signalling molecule (30 min; room
temperature), diluted in FoxP3-staining kit Perm/Wash
buffer. To determine BCR sensitivity, samples were cul-
tured in Rosswell Park Memorial Institute 1640 medium
with 2% fetal calf serum at 37C for 5 min in the pres-
ence/absence of 20 mg/ml anti-IgM (SouthernBiotech,
Birmingham, AL, USA) prior to fixation (see supplementary
Table S1, available at Rheumatology online, for antibo-
dies). Data were analysed by FlowJo software.
Intracellular cytokines by flow cytometry
After restimulation, cultured PBMCs were washed and
stained as described previously [19] (supplementary
Table S1, available at Rheumatology online, for antibo-
dies). Data were analysed using Kaluza v1.7 (Beckman
Coulter, Brea, CA, USA). FACS plots from unstimulated
samples were used to define gates (gating example in
supplementary Fig. S5, available at Rheumatology
online). One HC with <20% viable PBMCs was excluded.
In vitro plasma cell formation by flow cytometry
After 7-day culture, PBMCs were washed twice and
stained for 15 min with antibodies (supplementary Table
S1, available at Rheumatology online, for antibodies). Data
were analysed in Kaluza v1.7. CD27hiCD38hi plasma cell
frequencies were determined among CD19+CD22+ B cells
(supplementary Fig. S6, available at Rheumatology
online).
In vitro total IgG and PR3-ANCA
Total IgG levels (ng/ml) and PR3-ANCA IgG levels (re-
sponse units) were determined by ELISA and Phadia
ImmunoCAP 250 analyser, respectively, in supernatants
of anti-IgM Fab2/BAFF/IL-21-stimulated PBMCs after a
12-day culture, as described previously [21].
Statistics
Data were analysed using GraphPad Prism software
(GraphPad Prism Inc., La Jolla, CA, USA). Statistical dif-
ferences between groups were determined by one-way
ANOVA with a Tukey’s multiple comparison test or
Dunn’s test. Paired data were analysed using the
Wilcoxon signed-rank test. Correlations were analysed
by Spearman correlation test. P-values <0.05 were con-
sidered statistically significant.
Results
Increased BTK protein levels in transitional and naı¨ve
B cells from active GPA patients
The frequencies of various B cell subsets were quantified
in PBMCs from GPA patients and HCs by flow cytometry
(supplementary Fig. S3, available at Rheumatology
online). Likely due to low sample numbers, no significant
differences were found in B cell subset distribution be-
tween HCs and the patient groups, although plasmablasts
were slightly increased in active GPA patients.
Next, we determined BTK protein levels in different B
cell subsets. Compared with HCs, BTK protein levels were
increased in total B cells of active GPA patients, which
were similar to levels in the active ACPA+ RA patient con-
trol group. BTK protein levels were not different in remis-
sion GPA patients, and no differences were found
between ANCA+ and ANCA remission patients (Fig. 1A
and data not shown). Interestingly, comparable differ-
ences were observed in IgD+CD27 naı¨ve B cells and
CD38+CD27 transitional B cells from active compared
with remission GPA patients (Fig. 1B and C). These differ-
ences were not present in switched or non-switched
memory B cells or plasmablasts (Fig. 1DF), indicating
that the difference between active and remission patients
involves newly emerging B cells rather than antigen-
experienced B cells.
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Enhanced response to BCR stimulation in newly
emerging B cells of active GPA patients
To link BTK protein levels to its activity, we measured
pBTK at Y223 [12], as well as phosphorylation of several
up- and downstream signalling molecules in a smaller
group of patients. As previously shown for RA patients
[14], BTK protein levels in total B cells correlated with ex
vivo pBTK in HCs and active GPA patients (Fig. 2A). pBTK
was not different between HCs and GPA patients ex vivo
(Fig. 2B). Phosphorylation of the direct and specific BTK
downstream target phospholipase C (PLC) g2 (Y759),
which links BCR stimulation to Ca2+ signalling, appeared
increased both in transitional and naı¨ve B cells from active
and remission GPA patients, but the increase observed ex
vivo only reached significance for the difference between
HC and remission patients in the transitional B cell sub-
population (Fig. 2C and D). In contrast, no differences
were found in the phosphorylation of the BCR-associated
upstream molecule MB1 (CD79a), or the downstream
molecules ERK (MAPK pathway) and S6 (AKT pathway)
in directly fixed transitional or naı¨ve B cells between active
patients and HCs, nor in phosphorylation in memory B
cells (ex vivo, data not shown).
To further determine BCR sensitivity of different B cell
subsets, PBMCs from patients and HCs were stimulated
in vitro with anti-IgM Fab2 fragments. All groups showed
upregulation of pBTK in transitional and naı¨ve B cells upon
stimulation (Fig. 3A and B). However, B cell sensitivity,
measured by increased pBTK upon anti-IgM stimulation,
was significantly increased in these subsets from active
compared with remission GPA patients and HCs (Fig. 3C),
while sensitivity of memory B cell subsets was not
significantly different between the groups. Similar results
were obtained for pPLCg2 expression upon anti-IgM
stimulation (Fig. 3DF). Although the differences between
the groups did not reach significance for pPLCg2, the ex-
pressions of pPLCg2 and pBTK Y223 upon stimulation
were significantly correlated (r= 0.802; P = 0.007; supple-
mentary Fig. S4, available at Rheumatology online).
These data indicate that increased activity of BTK in
newly emerging B cells is correlated with increased BTK
protein levels in active GPA patients, and that this may
also affect its downstream target pPLCg2. These data
also suggest that sensitivity of the BCR signalling pathway
may be increased in transitional and naı¨ve B cells of active
GPA patients.
BTK protein levels correlate with B cell activity and
decreased circulating pro-inflammatory CD4+ T cells
in GPA patients
The increased BCR signalling in B cells of active GPA
patients suggested increased B cell activation. Surface
expression of co-stimulation molecule CD86 on total B
cells was moderately, but not significantly, increased in
active GPA patients (Fig. 4A). BTK protein levels in GPA
patients, but not in HCs, correlated with B cell CD86 ex-
pression, indicating that high BTK levels associate with
increased B cell activation in GPA patients (Fig. 4B).
We previously showed that BTK protein levels were
associated with increased pro-inflammatory CD4+ T cell
numbers in autoimmune patients [14]. Therefore, the pro-
portions and activation status of different T cell subsets in
FIG. 1 BTK protein levels are increased in B cells from active GPA patients compared with HCs and remission patients
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(A) BTK protein levels in total peripheral B cells from HCs, active GPA, remission GPA and RA patients, analysed by intra-
cellular flow cytometry. Depicted ratio is BTK MFI in B cells/BTK MFI in T cells. Histogram shows an overlay of a repre-
sentative HC and active GPA patient. (BF) BTK protein levels in naı¨ve B cells (B), transitional B cells (C), IgD+ non-switched
memory B cells (D), switched memory B cells (E) and plasmablasts (F). *P< 0.05; **P< 0.01; ***P< 0.001. act: active; BTK:
Bruton’s tyrosine kinase; GPA: granulomatosis with polyangiitis; HCs: healthy controls; MFI: mean fluorescence intensity.
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PBMCs from GPA patients and HCs were quantified.
Memory CD4+ T cell proportions were increased in remis-
sion but not in active GPA patients compared with HCs
(supplementary Fig. S5A, available at Rheumatology
online). Within the memory CD4+ T cell pool, pro-inflam-
matory T cell subsets implicated in autoimmunity
were generally decreased in active GPA patients
(supplementary Fig. S5B, available at Rheumatology
online), whereas anti-inflammatory subsets and non-auto-
immune associated Th2 cells were increased (supplemen-
tary Fig. S5C, available at Rheumatology online).
Interestingly, BTK protein levels were inversely correlated
with pro-inflammatory Th1 cells, and a trend was seen for
Th17.1, in GPA patients (Fig. 4C). Conversely, BTK levels
were positively correlated with the frequencies of Th2
cells, and a trend was seen for regulatory Tfr-like cells
(Fig. 4D). ICOS expression on Tfh-like cells in GPA
patients was not different from HCs (supplementary Fig.
S5D, available at Rheumatology online).
These data show that BTK protein levels in B cells cor-
relate with B cell activity and decreased circulating pro-
inflammatory CD4+ T cells in GPA patients.
BTK inhibition decreases in vitro IFNg+, IL-10+ and
IL-6+ B cell frequencies, plasma cell formation and
(auto)antibody production
To assess the functional importance of BTK in B cells of
GPA patients, PBMCs were stimulated with anti-IgM in the
absence or presence of a BTK inhibitor, and in vitro B cell
cytokine production was determined. Upon culture with-
out BTK inhibitor, no significant differences in cytokine-
positive B cell frequencies were found between groups.
In vitro BTK inhibition significantly decreased IFNg+, IL-
10+ and IL-6+ B cell frequencies in all groups (gating strat-
egy is shown in supplementary Fig. S6, available at
Rheumatology online). However, the TNFa+ B cell fre-
quency was only decreased in remission GPA patients.
Comparing the effect of BTK inhibition between groups
showed decreased IFNg+ B cell frequencies in remission
compared with active GPA patients (Fig. 5A).
The sensitivity of IL-10+ B cells to BTK inhibition was
decreased in active GPA patients compared with HCs, as
the ratio of anti-IgM/anti-IgM + BTK inhibitor was
decreased in active patients (supplementary Fig. S8A,
available at Rheumatology online). Together, cytokine-
positive B cell frequencies upon BTK inhibition are
decreased, and the effect is possibly lower in active
GPA patients.
To determine whether in vitro plasma cell formation is
affected by BTK inhibition, PBMCs were stimulated with
anti-IgM and BAFF in the absence or presence of a BTK
inhibitor. Upon culture without BTK inhibitor, no differ-
ences were found in memory B cell formation between
groups; however, plasma cell formation was increased
in active compared with remission GPA patients (for
gating strategy, see supplementary Fig. S7, available at
Rheumatology online). Upon in vitro BTK inhibition,
plasma cell formation was decreased in remission GPA
FIG. 2 Increased BCR activity in transitional and naı¨ve B cells of GPA patients ex vivo
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patients, but could not be decreased in active GPA
patients and HCs (Fig. 5B). Also, memory B cell formation
was decreased upon BTK inhibition in remission GPA
patients and HCs, but not in active GPA patients.
Interestingly, plasma cell frequencies were increased
upon BTK inhibition in active compared with remission
GPA patients (Fig. 5B). Importantly, transitional B cell fre-
quencies were not different between groups upon BTK
inhibition (supplementary Fig. S8B, available at
Rheumatology online). Naı¨ve B cell frequencies in the ab-
sence and presence of BTK inhibition were increased in
remission compared with active GPA patients and HCs
(supplementary Fig. S8B, available at Rheumatology on-
line). This indicates that the efficacy of BTK inhibition is
lower in active GPA patients.
To determine the effect of BTK inhibition on (auto)anti-
body secretion, PBMCs were cultured with anti-IgM,
BAFF and IL-21 in the absence or presence of the BTK
inhibitor for 12 days, and PR3-ANCA and total IgG con-
centrations were determined in supernatants. In cultures
of eight GPA patients, including five active patients, PR3-
ANCA were secreted and BTK inhibition appeared to de-
crease the PR3-ANCA levels (Fig. 5C). However, no sig-
nificant differences were found, possibly due to large
variation between samples. Total in vitro IgG production
was decreased in HCs and remission patients upon BTK
inhibition, whereas a trend towards a decrease was seen
in active GPA patients (Fig. 5C).
Together, these data show that BTK inhibition may de-
crease in vitro B cell differentiation towards memory B
cells and antibody-producing plasma cells in HCs and re-
mission GPA patients, but seemed less effective in active
GPA patients. Furthermore, BTK inhibition diminished in
vitro (auto)antibody production in remission and active
GPA patients.
Discussion
GPA is characterized by a high morbidity and is fatal if left
untreated. Although disease remission can be established
by immunosuppressive therapy, these treatments are not
directed specifically at pathogenic processes and can
FIG. 3 Increased in vitro BCR responsiveness in transitional and naı¨ve B cells of active GPA patients
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pBTK expression on transitional B cells (A) and naı¨ve B cells (B) in vitro, unstimulated (left) and upon stimulation with anti-
IgM Fab2 fragments for 5 min (aIgM; right). Histogram shows overlays of pBTK MFI of a representative HC and active GPA
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lead to severe side-effects [22]. New therapies that spe-
cifically target pathogenic pathways and cells involved in
GPA are therefore needed. Here we assessed BTK ex-
pression and the effect of BTK blockade on B cell function
as a novel treatment target in GPA.
Although GPA patients commonly receive medication at
the time of diagnosis, we were able to include nine un-
treated active GPA patients. Despite this low number, we
found clear differences in the BTK protein levels com-
pared with remission GPA patients and HCs. These pro-
tein levels correlated with BCR sensitivity and circulating
pro-inflammatory T cells. Furthermore, clear effects of in
vitro BTK inhibition on B cell effector functions were
observed in remission GPA patients and HCs, but were
less pronounced in active GPA patients, showing that with
the current sample size, active and remission patients can
be distinguished.
BTK levels were increased in some memory B cell sub-
sets in remission patients, but—most importantly—we
observed a striking difference between active disease
and remission in newly formed naı¨ve and transitional B
cells. Hereby only active GPA patients show increased
BTK protein levels compared with HCs. Transitional and
naı¨ve B cells from these patients show increased BCR
signalling ex vivo, as pPLCg2 levels were increased, as
well as increased BCR sensitivity in vitro, inferred from
the enhanced pBTK levels upon BCR stimulation. These
observations parallel our previous findings of increased
BTK protein levels in naı¨ve B cells of untreated active
RA and SS patients [14]. In these patients, BTK levels
correlated with autoantibodies. We did not find a correl-
ation with ANCA titres, possibly due to low sample num-
bers. Increased BTK protein levels in transitional and
naı¨ve B cells do correlate with a more activated B cell
phenotype in GPA patients, and a decrease in pro-inflam-
matory CD4+ T cell proportions in the circulation. We
therefore propose that pathogenic BT cell interaction
occurs already at an early stage of B cell differentiation,
and that newly emerging B cells may be actively involved
in autoimmune disease pathology.
We previously demonstrated correlations between BTK
levels and T cell activity in RA and SS patients and
showed that inhibition of BT cell or dendritic cellT cell
co-stimulation by abatacept was sufficient to reduce BTK
protein in naı¨ve B cells to HC levels [14]. In SS, B cell BTK
protein levels correlated with infiltrating T cell numbers in
parotid glands. Although target organs in GPA patients
were not studied here, it is conceivable that the numbers
of activated T cells involved in disease pathogenesis are
higher in target organs of active GPA patients than in
FIG. 4 BTK protein levels of B cells of GPA patients correlate with B cell activation and decreased pro-inflammatory T cell
subsets in the circulation
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FIG. 5 BTK blockade inhibits in vitro B cell cytokine production, plasma cell formation and (auto)antibody production
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remission patients. Normalized BTK expression in remis-
sion GPA patients and abatacept-treated SS patients both
indicate that BTK is not intrinsically dysregulated in auto-
immune patients, but that a pro-inflammatory micro-envir-
onment including activated T cells is responsible for
increased BTK expression and BCR activity.
B cells play an essential role in GPA pathogenesis as
ANCA-producing cells. As expected, BTK blockade in-
hibited in vitro plasma cell formation, PR3-ANCA and
total IgG production upon BCR stimulation. GPA patients
show increased B cell activation and activated effector B
cells may be an important source of pro-inflammatory
cytokines, although the contribution of these cytokines
to GPA pathogenesis is unclear [19]. Importantly, in vitro
BTK blockade resulted in inhibition of B cell cytokine pro-
duction (IFNg, IL-10, IL-6) in active and remission GPA
patients and HCs. Thus, BTK inhibition affects several B
cell effector functions in GPA B cells.
We also show a clear effect of in vitro BTK blockade on
plasma cell formation in remission patients, accompanied
by a decrease in memory B cells, whereas no such effect
was seen in active GPA patients. Altogether, in our in vitro
cultures of B cells from active GPA patients, the propor-
tions of differentiated plasma cells were increased com-
pared with remission patients and HCs. Although in vitro
effects on BCR signalling in Ramos cells were shown with
lower doses of the BTK inhibitor [20], it is possible that the
dose used in our study was insufficient to inhibit in vivo
activated B cells of active patients, or that activated B
cells in these patients no longer depend on BTK-mediated
survival signals. In vitro BTK inhibition significantly
reduced IgG production in remission GPA patients and
HCs, but not in active GPA patients. This suggests that
B cells in patients with active disease are more activated
and may require a higher dose of BTK inhibition to signifi-
cantly reduce IgG secretion. In the five samples from
active patients that produced PR3-ANCA in vitro, we
found reduced levels upon BTK inhibition, indicating that
BTK kinase activity may play an important role in autoanti-
body production.
Taken together, BTK protein levels were increased in
most B cell subsets of active GPA patients, including
newly emerging transitional and naı¨ve B cells, but only
in a limited number of memory B cell subsets in remis-
sion GPA patients. These levels are correlated with
enhanced BCR activity and sensitivity, and an increased
expression of the co-stimulatory molecule CD86 on B
cells. The correlation of B cell BTK levels with decreased
numbers of pro-inflammatory Th1 and T17.1 cells in the
circulation would be consistent with migration of these
pro-inflammatory T cells to target organs during active
disease. This might be supported by our previous finding
in SS patients that BTK protein levels in circulating B
cells correlated with T cell infiltration in the salivary
glands [14].
Furthermore, we found that BTK inhibition in vitro can
inhibit B cell cytokine production, plasma cell formation
and total IgG (auto)antibody secretion. Although B cells
from active GPA patients respond less to BTK inhibition
in vitro than healthy B cells, further studies in larger patient
cohorts may identify BTK as an interesting novel thera-
peutic target in GPA patients.
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